Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967204 | 0.91 | EPHX1 (0.36) | EPHX1SMN1; SMN2 | |
| SCHEMBL14966833 | 0.91 | EPHX1 (0.40) | CYP19A1EPHX1SMN1; SMN2 | |
| SCHEMBL14966797 | 0.90 | EPHX1 (0.43) | CYP19A1EPHX1SMN1; SMN2 | |
| SCHEMBL11193873 | 0.83 | CYP19A1 (0.39) | PPM1BPTPN1PPP1CCCYP19A1EPHX1 | |
| SCHEMBL16488191 | 0.77 | SERPINE1 (0.31) | SERPINE1 | |
| SCHEMBL15326522 | 0.77 | MAPK1 (0.38) | — | |
| SCHEMBL15412666 | 0.76 | — | — | |
| SCHEMBL14967440 | 0.75 | PPM1B (0.35) | PPM1BPTPN1PPP1CCCYP19A1TSHR | |
| SCHEMBL11188748 | 0.74 | EPHX1 (0.42) | CYP19A1EPHX1SMN1; SMN2 | |
| SCHEMBL11194073 | 0.73 | EPHX1 (0.45) | CYP19A1EPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301397-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2019-05-28 | — | — | US | disclosed |
| EP-2837629-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LABORATORIES (TIANJIN) CO LTD (CN) | 2017-03-22 | — | — | EP | disclosed |
| US-20160340447-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9458270-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9371326-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-21 | — | — | US | disclosed |
| US-9371326-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-21 | — | — | US | disclosed |
| EP-2780177-B1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORP (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-30 | — | — | US | disclosed |
| EP-2837629-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | disclosed |
| US-20140296445-A1 | Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow | BRIDGESTONE CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2780177-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | Bridgestone Corporation (JP) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013152608-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | 凯莱英医药集团（天津）股份有限公司 (CN) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013075074-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | DHCR7, CYP51A1, HMGCR | PPM1B 2067/4885PTPN1 4216/4885PPP1CC 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.